A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage

Annals of Oncology

Volumn 26, Issue 4, 2015, Pages 624-644

  Findlay, John M ^a,b   Middleton, M R ^c   Tomlinson, I ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Oxford OesophagoGastric Centre   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Biomarkers; Cancer; Cancer staging; Esophageal; Genomic; Prognosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLEOMYCIN; CISPLATIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FIBROBLAST GROWTH FACTOR 3; FLUOROURACIL; GEFITINIB; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; PLATINUM DERIVATIVE; PROTEIN MDM2; PROTEIN P53; TAXANE DERIVATIVE; TUMOR MARKER; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ABCB1 GENE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CCND1 GENE; CHEMORADIOTHERAPY; CHROMOSOMAL INSTABILITY; COPY NUMBER VARIATION; DISEASE FREE SURVIVAL; DNA SEQUENCE; ERBB2 GENE; ERCC1 GENE; ESOPHAGUS CANCER; ESOPHAGUS SURGERY; FGF3 GENE; GENE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GERMLINE MUTATION; HER2 GENE; HETEROZYGOSITY LOSS; HIGH THROUGHPUT SEQUENCING; HUMAN; MDM2 GENE; MICROSATELLITE INSTABILITY; MTHFR GENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PIK3CA GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; SYSTEMATIC REVIEW; TP53 GENE; TREATMENT RESPONSE; TYMS GENE; ESOPHAGEAL NEOPLASMS; GENETICS; META ANALYSIS; MORTALITY; PROGNOSIS;

BIOMARKERS, TUMOR; DNA, NEOPLASM; ESOPHAGEAL NEOPLASMS; GERM-LINE MUTATION; HUMANS; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

EID: 84926434070     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu449     Document Type: Review

References (192)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-781.
2. Lepage C, Rachet B, Jooste V et al. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol 2008; 103: 2694-2699.
3. Lagergren J, Bergstrom R, Lindgren A et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-831.
4. Rodgers M, Jobe BA, O'Rourke RW et al. Case volume as a predictor of inpatient mortality after esophagectomy. Arch Surg 2007; 142: 829-839.
5. Unit RCoSCE. National Oesophago-Gastric Cancer Audit 2012. London: Royal College Of Surgeons of England 2012.
6. Findlay JM, Tustian E, Millo J et al. The effect of formalizing enhanced recovery after esophagectomy with a protocol. Dis Esophagus 2014 [Epub ahead of print].
7. Scarpa M, Saadeh LM, Fasolo A et al. Health-related quality of life in patients with oesophageal cancer: analysis at different steps of the treatment pathway. J Gastrointest Surg 2013; 17: 421-433.
8. Djarv T, Derogar M, Lagergren P. Influence of co-morbidity on long-term quality of life after oesophagectomy for cancer. Br J Surg 2014; 101: 495-501.
9. Gebski V, Burmeister B, Smithers BM et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8: 226-234.
10. Campbell NP, Villaflor VM. Neoadjuvant treatment of esophageal cancer. World J Gastroenterol 2010; 16: 3793-3803.
11. Rouvelas I, Zeng W, Lindblad M et al. Survival after surgery for oesophageal cancer: a population-based study. Lancet Oncol 2005; 6: 864-870.
12. Jamieson GG, Mathew G, Ludemann R et al. Postoperative mortality following oesophagectomy and problems in reporting its rate. Br J Surg 2004; 91: 943-947.
13. Davies AR, Pillai A, Sinha P et al. Factors associated with early recurrence and death after esophagectomy for cancer. J Surg Oncol 2014; 109: 459-464.
14. Allum WH, Blazeby JM, Griffin SM et al. Guidelines for the management of oesophageal and gastric cancer. Gut 2011; 60: 1449-1472.
15. Chan DS, Twine CP, Lewis WG. Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer. J Gastrointest Surg 2012; 16: 1821-1829.
16. Dulak AM, Stojanov P, Peng S et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 2013; 45: 478-486.
17. Agrawal N, Jiao Y, Bettegowda C et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov 2012; 2: 899-905.
18. Streppel MM, Lata S, DelaBastide M et al. Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagus. Oncogene 2014; 33: 347-357.
19. Kim JC, Kim SY, Cho DH et al. Novel chemosensitive single-nucleotide polymorphism markers to targeted regimens in metastatic colorectal cancer. Clin Cancer Res 2011; 17: 1200-1209.
20. Patel JN, McLeod HL, Innocenti F. Implications of genome-wide association studies in cancer therapeutics. Br J Clin Pharmacol 2013; 76: 370-380.
21. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol 2010; 17: 1721-1724.
22. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
23. Gray KA, Daugherty LC, Gordon SM et al. Genenames.org: the HGNC resources in 2013. Nucleic Acids Res 2013; 41: D545-D552.
24. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ 1995; 310: 170.
25. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101: 1446-1452.
26. International HapMap C. The International HapMap Project. Nature 2003; 426: 789-796.
27. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform metaanalyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834.
28. Miller CT, Moy JR, Lin L et al. Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. Clin Cancer Res 2003; 9: 4819-4825.
29. Uchino S, Saito T, Inomata M et al. Prognostic significance of the p53 mutation in esophageal cancer. Jpn J Clin Oncol 1996; 26: 287-292.
30. Chikuba K, Saito T, Uchino S et al. High amplification of the hst-1 gene correlates with haematogenous recurrence after curative resection of oesophageal carcinoma. Br J Surg 1995; 82: 364-367.
31. Itakura Y, Sasano H, Shiga C et al. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994; 74: 795-804.
32. Wang LS, Chow KC, Chi KH et al. Prognosis of esophageal squamous cell carcinoma: analysis of clinicopathological and biological factors. Am J Gastroenterol 1999; 94: 1933-1940.
33. Warnecke-Eberz U, Vallbohmer D, Alakus H et al. ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer. J Gastrointest Surg 2009; 13: 1411-1421.
34. Sterne JA, Sutton AJ, Ioannidis JP et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011; 343: d4002.
35. Higgins J, Green SP. Cochrane Handbook for Systematic Reviews of Interventions. Oxford: Wiley-Blackwell 2008.
36. Sutton AJ, Duval SJ, Tweedie RL et al. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000; 320: 1574-1577.
37. Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing 2013.
38. Casson AG, Evans SC, Gillis A et al. Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study. J Thorac Cardiovasc Surg 2003; 125: 1121-1131.
39. Schneider PM, Stoeltzing O, Roth JA et al. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus. Clin Cancer Res 2000; 6: 3153-3158.
40. Madani K, Zhao R, Lim HJ et al. Prognostic value of p53 mutations in oesophageal adenocarcinoma: final results of a 15-year prospective study. Eur J Cardiothorac Surg 2010; 37: 1427-1432.
41. Yamasaki M, Miyata H, Fujiwara Y et al. p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus. Ann Surg Oncol 2010; 17: 634-642.
42. Kobayashi S, Koide Y, Endo M et al. The p53 gene mutation is of prognostic value in esophageal squamous cell carcinoma patients in unified stages of curability. Am J Surg 1999; 177: 497-502.
43. Ribeiro U, Jr, Finkelstein SD, Safatle-Ribeiro AV et al. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 1998; 83: 7-18.
44. Kandioler D, Schoppmann SF, Zwrtek R et al. The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study. J Thorac Cardiovasc Surg 2014 [Epub ahead of print].
45. Puhringer-Oppermann F, Stahl M, Keller G et al. Lack of prognostic impact of p53 gene mutation and p53 phosphorylation at serine 15 in multimodally treated adenocarcinomas of the gastroesophageal junction. J Cancer Res Clin Oncol 2006; 132: 433-438.
46. Soontrapornchai P, Elsaleh H, Joseph D et al. TP53 gene mutation status in pretreatment biopsies of oesophageal adenocarcinoma has no prognostic value. Eur J Cancer 1999; 35: 1683-1687.
47. Makino T, Yamasaki M, Miyata H et al. p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer. Ann Surg Oncol 2010; 17: 804-811.
48. Shimada Y, Imamura M, Shibagaki I et al. Genetic alterations in patients with esophageal cancer with short- and long-term survival rates after curative esophagectomy. Ann Surg 1997; 226: 162-168.
49. Egashira A, Morita M, Yoshida R et al. Loss of p53 in esophageal squamous cell carcinoma and the correlation with survival: analyses of gene mutations, protein expression, and loss of heterozygosity in Japanese patients. J Surg Oncol 2011; 104: 169-175.
50. Ito T, Kaneko K, Makino R et al. Prognostic value of p53 mutations in patients with locally advanced esophageal carcinoma treated with definitive chemoradiotherapy. J Gastroenterol 2001; 36: 303-311.
51. Lam KY, Tsao SW, Zhang D et al. Prevalence and predictive value of p53 mutation in patients with oesophageal squamous cell carcinomas: a prospective clinico-pathological study and survival analysis of 70 patients. Int J Cancer 1997; 74: 212-219.
52. Shibagaki I, Tanaka H, Shimada Y et al. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma. Clin Cancer Res 1995; 1: 769-773.
53. Goan YG, Hsu HK, Chang HC et al. Deregulated p21(WAF1) overexpression impacts survival of surgically resected esophageal squamous cell carcinoma patients. Ann Thorac Surg 2005; 80: 1007-1016.
54. Cao W, Chen X, Dai H et al. Mutational spectra of p53 in geographically localized esophageal squamous cell carcinoma groups in China. Cancer 2004; 101: 834-844.
55. Gibson MK, Abraham SC, Wu TT et al. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 2003; 9: 6461-6468.
56. Coggi G, Bosari S, Roncalli M et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer 1997; 79: 425-432.
57. Izzo JG, Wu TT, Wu X et al. Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. J Clin Oncol 2007; 25: 698-707.
58. Shigaki H, Baba Y, Watanabe M et al. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma. Clin Cancer Res 2013; 19: 2451-2459.
59. Marx AH, Zielinski M, Kowitz CM et al. Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. Histopathology 2010; 57: 418-426.
60. Kitagawa Y, Ueda M, Ando N et al. Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res 1996; 2: 909-914.
61. Lennerz JK, Kwak EL, Ackerman A et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011; 29: 4803-4810.
62. Luber B, Deplazes J, Keller G et al. Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophagogastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer 2011; 11: 509.
63. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006; 24: 1612-1619.
64. Sunpaweravong P, Sunpaweravong S, Puttawibul P et al. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2005; 131: 111-119.
65. Prins MJ, Ruurda JP, van Diest PJ et al. The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study. Ann Oncol 2013; 24: 1290-1297.
66. Rauser S, Weis R, Braselmann H et al. Significance of HER2 low-level copy gain in Barrett's cancer: implications for fluorescence in situ hybridization testing in tissues. Clin Cancer Res 2007; 13: 5115-5123.
67. Brien TP, Odze RD, Sheehan CE et al. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum Pathol 2000; 31: 35-39.
68. Zhan N, Dong WG, Tang YF et al. Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma. Med Oncol 2012; 29: 933-940.
69. Sato-Kuwabara Y, Neves JI, Fregnani JH et al. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry. BMC Cancer 2009; 9: 6.
70. Mimura K, Kono K, Hanawa M et al. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 2005; 92: 1253-1260.
71. Yoon HH, Shi Q, Sukov WR et al. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol 2012; 30: 3932-3938.
72. Thompson SK, Sullivan TR, Davies R et al. Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival. Ann Surg Oncol 2011; 18: 2010-2017.
73. Konig AM, Reeh M, Dancau AM et al. Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma. Anticancer Res 2013; 33: 4975-4982.
74. Suzuki H, Abo S, Kitamura M et al. Gene amplification of int-2 and erbB in human esophageal cancer: relationship to clinicopathological variables. Cancer Invest 1997; 15: 411-415.
75. Ikeda Y, Ozawa S, Ando N et al. Meanings of c-erbB and int-2 amplification in superficial esophageal squamous cell carcinomas. Ann Thorac Surg 1996; 62: 835-838.
76. Wang MT, Chen G, An SJ et al. Prognostic significance of cyclinD1 amplification and the co-alteration of cyclinD1/pRb/ppRb in patients with esophageal squamous cell carcinoma. Dis Esophagus 2012; 25: 664-670.
77. Takeshita H, Ichikawa D, Komatsu S et al. Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma. Br J Cancer 2010; 102: 1378-1383.
78. Shinozaki H, Ozawa S, Ando N et al. Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. Clin Cancer Res 1996; 2: 1155-1161.
79. Komatsu S, Ichikawa D, Hirajima S et al. Clinical impact of predicting CCND1 amplification using plasma DNA in superficial esophageal squamous cell carcinoma. Dig Dis Sci 2014; 59: 1152-1159.
80. Gramlich TL, Fritsch CR, Maurer D et al. Differential polymerase chain reaction assay of cyclin D1 gene amplification in esophageal carcinoma. Diagn Mol Pathol 1994; 3: 255-259.
81. Carneiro A, Isinger A, Karlsson A et al. Prognostic impact of array-based genomic profiles in esophageal squamous cell cancer. BMC Cancer 2008; 8: 98.
82. Mori M, Tokino T, Yanagisawa A et al. Association between chromosome 11q13 amplification and prognosis of patients with oesophageal carcinomas. Eur J Cancer 1992; 28A: 755-757.
83. Wang YF, Wang XS, Gao SG et al. Clinical significance of combined detection of human papilloma virus infection and human telomerase RNA component gene amplification in patients with squamous cell carcinoma of the esophagus in northern China. Eur J Med Res 2013; 18: 11.
84. Shi ZZ, Liang JW, Zhan T et al. Genomic alterations with impact on survival in esophageal squamous cell carcinoma identified by array comparative genomic hybridization. Genes Chromosomes Cancer 2011; 50: 518-526.
85. Gertler R, Doll D, Maak M et al. Telomere length and telomerase subunits as diagnostic and prognostic biomarkers in Barrett carcinoma. Cancer 2008; 112: 2173-2180.
86. Ikeguchi M, Unate H, Maeta M et al. Detection of loss of heterozygosityat microsatellite loci in esophageal squamous-cell carcinoma. Oncology 1999; 56: 164-168.
87. Maru DM, Luthra R, Correa AM et al. Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival. Cancer 2009; 115: 1576-1585.
88. Doki Y, Shiozaki H, Tahara H et al. Prognostic value of DNA ploidy in squamous cell carcinoma of esophagus. Analyzed with improved flow cytometric measurement. Cancer 1993; 72: 1813-1818.
89. Tsutsui S, Kuwano H, Mori M et al. A flow cytometric analysis of DNA content in primary and metastatic lesions of esophageal squamous cell carcinoma. Cancer 1992; 70: 2586-2591.
90. Kaketani K, Saito T, Kobayashi M. Flow cytometric analysis of nuclear DNA content in esophageal cancer. Aneuploidy as an index for highly malignant potential. Cancer 1989; 64: 887-891.
91. Ohno S, Korenaga D, Kuwano H et al. DNA aneuploidy assessment of the effectiveness of hyperthermo-chemo-radiotherapy for esophageal carcinoma. Cancer 1989; 63: 1951-1955.
92. Kuwano H, Sumiyoshi K, Nozoe T et al. The prognostic significance of the cytophotometric DNA content and its relationship with the argyrophilic nucleolar organizer regions (AgNOR) and proliferating cell nuclear antigen (PCNA) in oesophageal cancer. Eur J Surg Oncol 1995; 21: 368-373.
93. Edwards JM, Jones DJ, Wilkes SJ et al. Ploidy as a prognostic indicator in oesophageal squamous carcinoma and its relationship to various histological criteria. J Pathol 1989; 159: 35-41.
94. Deguchi S, Muto Y, Kusano T et al. Intratumoral heterogeneity of DNA ploidy and regional differences in epidermal growth factor and epidermal growth factor receptor of esophageal carcinoma. Tohoku J Exp Med 1993; 171: 107-118.
95. Bradbury PA, Kulke MH, Heist RS et al. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics 2009; 19: 613-625.
96. Wang Y, Chen J, Li X et al. Genetic polymorphisms of ERCC1 and their effects on the efficacy of cisplatin-based chemotherapy in advanced esophageal carcinoma. Oncol Rep 2011; 25: 1047-1052.
97. Rumiato E, Cavallin F, Boldrin E et al. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy. Pharmacogenet Genomics 2013; 23: 597-604.
98. Ott K, Rachakonda PS, Panzram B et al. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy. Ann Surg Oncol 2011; 18: 2688-2698.
99. Wu C, Li M, Hu C et al. Prognostic role of microRNA polymorphisms in patients with advanced esophageal squamous cell carcinoma receiving platinum-based chemotherapy. Cancer Chemother Pharmacol 2014; 73: 335-341.
100. Yang PW, Huang YC, Hsieh CY et al. Association of miRNA-related genetic polymorphisms and prognosis in patients with esophageal squamous cell carcinoma. Ann Surg Oncol, 2014 [Epub ahead of print].
101. Vashist YK, Trump F, Gebauer F et al. EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer. Target Oncol 2014; 9: 43-52.
102. Motoyama S, Nakatsu T, Miura M et al. Interleukin-6-634G>C genetic polymorphism is associated with prognosis following surgery for advanced thoracic esophageal squamous cell carcinoma. Dig Surg 2012; 29: 194-201.
103. Lee JM, Yang PW, Yang SY et al. Genetic variants in DNA repair predicts the survival of patients with esophageal cancer. Ann Surg 2011; 253: 918-927.
104. Yang PW, Hsieh CY, Kuo FT et al. The survival impact of XPA and XPC genetic polymorphisms on patients with esophageal squamous cell carcinoma. Ann Surg Oncol 2013; 20: 562-571.
105. Kaneko K, Nagai M, Murakami Y et al. TS gene tandem repeats in esophageal cancer patients receiving chemoradiotherapy. Front Biosci 2011; 16: 1036-1043.
106. Okuno T, Tamura T, Yamamori M et al. Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese. Am J Clin Oncol 2007; 30: 252-257.
107. Sarbia M, Stahl M, von Weyhern C et al. The prognostic significance of genetic polymorphisms (Methylenetetrahydrofolate Reductase C677T, Methionine Synthase A2756G, Thymidilate Synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma. Br J Cancer 2006; 94: 203-207.
108. Renouf DJ, Zhai R, Sun B et al. Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma. J Gastroenterol Hepatol 2013; 28: 1482-1488.
109. Boonstra JJ, van Marion R, Tilanus HW et al. Functional polymorphisms associated with disease-free survival in resected carcinoma of the esophagus. J Gastrointest Surg 2011; 15: 48-56.
110. Cescon DW, Bradbury PA, Asomaning K et al. p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis. Clin Cancer Res 2009; 15: 3103-3109.
111. Pan JY, Ajani JA, Gu J et al. Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation. Cancer 2012; 118: 4346-4353.
112. Tamura T, Kuwahara A, Yamamori M et al. VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatinbased chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int J Med Sci 2012; 9: 833-837.
113. Yang PW, Hsieh MS, Huang YC et al. Genetic variants of EGF and VEGF predict prognosis of patients with advanced esophageal squamous cell carcinoma. PLoS One 2014; 9: e100326.
114. Lorenzen S, Panzram B, Keller G et al. Association of the VEGF 936C>T polymorphism with FDG uptake, clinical, histopathological, and metabolic response in patients with adenocarcinomas of the esophagogastric junction. Mol Imaging Biol 2011; 13: 178-186.
115. Bradbury PA, Zhai R, Ma C et al. Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. Clin Cancer Res 2009; 15: 4680-4685.
116. Motoyama S, Miura M, Hinai Y et al. Interleukin-2-330T>G genetic polymorphism associates with prognosis following surgery for thoracic esophageal squamous cell cancer. Ann Surg Oncol 2011; 18: 1995-2002.
117. Tang RG, Huang YZ, Yao LM et al. Polymorphisms of transforming growth factor beta 1 (RS#1800468 and RS#1800471) and esophageal squamous cell carcinoma among Zhuangese population, China. Gene 2013; 512: 1-5.
118. Wu C, Li D, Jia W et al. Genome-wide association study identifies common variants in SLC39A6 associated with length of survival in esophageal squamouscell carcinoma. Nat Genet 2013; 45: 632-638.
119. Zhang R, Wang R, Zhang F et al. Single nucleotide polymorphisms in the mitochondrial displacement loop and outcome of esophageal squamous cell carcinoma. J Exp Clin Cancer Res 2010; 29: 155.
120. Umar M, Upadhyay R, Kumar S et al. CASP8-652 6N del and CASP8 IVS12-19G>A gene polymorphisms and susceptibility/prognosis of ESCC: a case control study in northern Indian population. J Surg Oncol 2011; 103: 716-723.
121. Lee JM, Wu MT, Lee YC et al. Association of GSTP1 polymorphism and survival for esophageal cancer. Clin Cancer Res 2005; 11: 4749-4753.
122. Wu X, Gu J, Wu TT et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 2006; 24: 3789-3798.
123. Lee JM, Yang SY, Yang PW et al. Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery. Ann Surg Oncol 2011; 18: 2066-2073.
124. Alakus H, Bollschweiler E, Holscher AH et al. Homozygous GNAS 393C-allele carriers with locally advanced esophageal cancer fail to benefit from platinumbased preoperative chemoradiotherapy. Ann Surg Oncol, 2014 [Epub ahead of print].
125. Vashist YK, Kutup A, Musici S et al. The GNAS1 T393C single nucleotide polymorphism predicts the natural postoperative course of complete resected esophageal cancer. Cell Oncol (Dordr) 2011; 34: 281-288.
126. Alakus H, Warnecke-Eberz U, Bollschweiler E et al. GNAS1 T393C polymorphism is associated with histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Pharmacogenomics J 2009; 9: 202-207.
127. Kaifi JT, Rawnaq T, Schurr PG et al. Short tandem repeat polymorphism in exon 4 of esophageal cancer-related gene 2 detected in genomic DNA is a prognostic marker for esophageal cancer. Am J Surg 2007; 194: 380-384.
128. Lu C, Xie H, Wang F et al. Diet folate, DNA methylation and genetic polymorphisms of MTHFR C677T in association with the prognosis of esophageal squamous cell carcinoma. BMC Cancer 2011; 11: 91.
129. Umar M, Upadhyay R, Khurana R et al. Evaluation of MTHFR677C>T polymorphism in prediction and prognosis of esophageal squamous cell carcinoma: a case-control study in a northern Indian population. Nutr Cancer 2010; 62: 743-749.
130. Narumiya K, Metzger R, Bollschweiler E et al. Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer. Pharmacogenomics 2011; 12: 205-214.
131. Lurje G, Leers JM, Pohl A et al. Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus. Ann Surg 2010; 251: 857-864.
132. Shibagaki I, Shimada Y, Wagata T et al. Allelotype analysis of esophageal squamous cell carcinoma. Cancer Res 1994; 54: 2996-3000.
133. Hildebrandt MA, Yang H, Hung MC et al. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 2009; 27: 857-871.
134. Azim K, McManus R, Brophy K et al. Genetic polymorphisms and the risk of infection following esophagectomy. Positive association with TNF-alpha gene -308 genotype. Ann Surg 2007; 246: 122-128.
135. Lee JM, Lo AC, Yang SY et al. Association of angiotensin-converting enzyme insertion/deletion polymorphism with serum level and development of pulmonary complications following esophagectomy. Ann Surg 2005; 241: 659-665.
136. Motoyama S, Miura M, Hinai Y et al. Interferon-gamma 874A>T genetic polymorphism is associated with infectious complications following surgery in patients with thoracic esophageal cancer. Surgery 2009; 146: 931-938.
137. Metzger R, Warnecke-Eberz U, Alakus H et al. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis. J Gastrointest Surg 2012; 16: 26-34; discussion 34.
138. Hattori K, Kajiyama Y, Tsurumaru M. Mutation of the p53 gene predicts lymph node metastases in Japanese patients with esophageal carcinoma: DNA and immunohistochemical analyses. Dis Esophagus 2003; 16: 301-306.
139. Wang XC, Wu YP, Ye B et al. Suppression of anoikis by SKP2 amplification and overexpression promotes metastasis of esophageal squamous cell carcinoma. Mol Cancer Res 2009; 7: 12-22.
140. Yang YL, Chu JY, Luo ML et al. Amplification of PRKCI, located in 3q26, is associated with lymph node metastasis in esophageal squamous cell carcinoma. Genes Chromosomes Cancer 2008; 47: 127-136.
141. Reichelt U, Duesedau P, Tsourlakis M et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007; 20: 120-129.
142. al-Kasspooles M, Moore JH, Orringer MB et al. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 1993; 54: 213-219.
143. Yang YL, Xu KL, Zhou Y et al. Correlation of epidermal growth factor receptor overexpression with increased epidermal growth factor receptor gene copy number in esophageal squamous cell carcinomas. Chin Med J (Engl) 2012; 125: 450-454.
144. Qin YR, Fu L, Sham PC et al. Single-nucleotide polymorphism-mass array reveals commonly deleted regions at 3p22 and 3p14.2 associate with poor clinical outcome in esophageal squamous cell carcinoma. Int J Cancer 2008; 123: 826-830.
145. Huang XP, Wei F, Liu XY et al. Allelic loss on 13q in esophageal squamous cell carcinomas from northern China. Cancer Lett 2002; 185: 87-94.
146. Harada H, Tanaka H, Shimada Y et al. Lymph node metastasis is associated with allelic loss on chromosome 13q12-13 in esophageal squamous cell carcinoma. Cancer Res 1999; 59: 3724-3729.
147. Yu JM, Yang LH, Guo Q et al. Flow cytometric analysis DNA content in esophageal carcinoma. Correlation with histologic and clinical features. Cancer 1989; 64: 80-82.
148. Matsumoto Y, Nagasaka T, Kambara T et al. Microsatellite instability and clinicopathological features in esophageal squamous cell cancer. Oncol Rep 2007; 18: 1123-1127.
149. Wang K, Li J, Guo H et al. MiR-196a binding-site SNP regulates RAP1A expression contributing to esophageal squamous cell carcinoma risk and metastasis. Carcinogenesis 2012; 33: 2147-2154.
150. Umar M, Upadhyay R, Kumar S et al. Modification of risk, but not survival of esophageal cancer patients by esophageal cancer-related gene 1 Arg290Gln polymorphism: a case-control study and meta-analysis. J Gastroenterol Hepatol 2013; 28: 1717-1724.
151. Miao X, Sun T, Wang Y et al. Functional STK15 Phe31Ile polymorphism is associated with the occurrence and advanced disease status of esophageal squamous cell carcinoma. Cancer Res 2004; 64: 2680-2683.
152. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
153. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21: 1559-1573.
154. Talsma K, van Hagen P, Grotenhuis BA et al. Comparison of the 6th and 7th Editions of the UICC-AJCC TNM Classification for Esophageal Cancer. Ann Surg Oncol 2012; 19: 2142-2148.
155. Olivier M, Langerod A, Carrieri P et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006; 12: 1157-1167.
156. Smith FM, Stephens RB, Kennedy MJ et al. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005; 92: 1813.
157. Xu J, Reumers J, Couceiro JR et al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol 2011; 7: 285-295.
158. Lehmann S, Bykov VJ, Ali D et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 2012; 30: 3633-3639.
159. Bellini MF, Cadamuro AC, Succi M et al. Alterations of the TP53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol 2012; 2012: 891961.
160. Lai PB, Chi TY, Chen GG. Different levels of p53 induced either apoptosis or cell cycle arrest in a doxycycline-regulated hepatocellular carcinoma cell line in vitro. Apoptosis 2007; 12: 387-393.
161. Coffill CR, Muller PA, Oh HK et al. Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion. EMBO Rep 2012; 13: 638-644.
162. Chen M, Huang J, Zhu Z et al. Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer. BMC Cancer 2013; 13: 539.
163. Zhang SS, Huang QY, Yang H et al. Correlation of p53 status with the response to chemotherapy-based treatment in esophageal cancer: a meta-analysis. Ann Surg Oncol 2013; 20: 2419-2427.
164. Eguchi K, Yao T, Konomoto T et al. Discordance of p53 mutations of synchronous colorectal carcinomas. Mod Pathol 2000; 13: 131-139.
165. Sim NL, Kumar P, Hu J et al. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res 2012; 40: W452-W457.
166. Adzhubei IA, Schmidt S, Peshkin L et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248-249.
167. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
168. Bible KC, Peethambaram PP, Oberg AL et al. A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261. Gynecol Oncol 2012; 127: 55-62.
169. Luke JJ, D'Adamo DR, Dickson MA et al. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. Clin Cancer Res 2012; 18: 2638-2647.
170. Lorenzen S, Schuster T, Porschen R et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009; 20: 1667-1673.
171. Rodriguez CP, Adelstein DJ, Rice TW et al. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J Thorac Oncol 2010; 5: 229-235.
172. Idelevich E, Kashtan H, Klein Y et al. Prospective phase II study of neoadjuvant therapy with cisplatin, 5-fluorouracil, and bevacizumab for locally advanced resectable esophageal cancer. Onkologie 2012; 35: 427-431.
173. De Vita F, Orditura M, Martinelli E et al. A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. Br J Cancer 2011; 104: 427-432.
174. Walther A, Houlston R, Tomlinson I. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut 2008; 57: 941-950.
175. Zhou W, Gurubhagavatula S, Liu G et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004; 10: 4939-4943.
176. Yin M, Yan J, Martinez-Balibrea E et al. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res 2011; 17: 1632-1640.
177. Giovannetti E, Pacetti P, Reni M et al. Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics 2011; 12: 1641-1652.
178. Li Y, Liu Z, Liu H et al. ERCC1 and ERCC2 variants predict survival in gastric cancer patients. PLoS One 2013; 8: e71994.
179. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478.
180. Wu H, Kang H, Liu Y et al. Association of ABCB1 genetic polymorphisms with susceptibility to colorectal cancer and therapeutic prognosis. Pharmacogenomics 2013; 14: 897-911.
181. Bond GL, Hu W, Bond EE et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591-602.
182. Ma Y, Bian J, Cao H. MDM2 SNP309 rs2279744 polymorphism and gastric cancer risk: a meta-analysis. PLoS One 2013; 8: e56918.
183. Horie N, Takeishi K. Functional structure of the promoter region of the human thymidylate synthase gene and nuclear factors that regulate the expression of the gene. Nucleic Acids Symp Ser 1995; 0: 77-78.
184. Lima A, Seabra V, Martins S et al. Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Mol Biol Rep 2014; 41: 3349-3357.
185. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
186. Boccia S, Hung R, Ricciardi G et al. Meta- and pooled analyses of the methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer risk: a huge-GSEC review. Am J Epidemiol 2008; 167: 505-516.
187. Abdel-Rahman SZ, El-Zein RA. The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Lett 2000; 159: 63-71.
188. Cui Z, Yin Z, Li X et al. Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis. BMC Cancer 2012; 12: 71.
189. Yu JJ, Lee KB, Mu C et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 2000; 16: 555-560.
190. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
191. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 6: 107-116.
192. Simon R, Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov 2013; 12: 358-369.